131I-Metaiodobenzylguanidine (mIBG) Archives

Tag: 131I-Metaiodobenzylguanidine (mIBG)

Iodine-131 meta-iodobenzylguanidine (I-131 MIBG) is a radiopharmaceutical used for both imaging and treating certain types of neuroendocrine tumours. Neuroendocrine tumours that can be treated with I-131 MIBG include neuroblastomas, paragangliomas and pheochromocytomas.

This targeted radionuclide therapy is able to detect and treat these tumours because the compound mIBG is very similar to norepinephrine/noradrenaline, a neurotransmitter chemical that is taken up by certain neuroendocrine cells. I-131 mIBG is used to treat neuroendocrine tumours by selectively targeting and killing neuroendocrine tumours that take up mIBG. See my article on scans – click here

Living with Neuroendocrine Cancer, Survivorship111In-DTPA-D-Phe1, 123I-Metaiodobenzylguanidine (mIBG), 131I-Metaiodobenzylguanidine (mIBG), 18F-FDG, 18F-FDOPA, Advanced neuroendocrine cancer, CT enterography, CT scan, Diagnosis, DOTA-NOC, DOTA-TATE, DOTA-TOC, Echocardiogram, Endoscopic ultrasound (EUS), Endoscopy, Explorer PET scan, Fluoro-18-L-Dihydroxyphenylalanine, Ga68 PET/CT, Magnetic resonance imaging (MRI) scan, Medullary thyroid cancer (MTC), Metastatic Neuroendocrine Cancer, Neuroblastoma, Neuroendocrine, Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Octreoscan (Octreotide scan), Octreotide scan, Paraganglioma, Pentetreotide, Pheochromocytoma, Somatostatin analogues, Somatostatin receptor scintigraphy (SRS), SPECT, SSTR-PET, Survivorship, Technetium-99m (Tc-99m), Ultrasound, X-ray

Neuroendocrine Cancer – If you can see it, you can detect it!

By Ronny Allan Jan 14, 2025 8 Comments

A Spotlight on NENs - Testing Series, Patient Advocacy131I-Metaiodobenzylguanidine (mIBG), 5-HIAA, 5-HT, 5-HTP, 5-Hydrotryptophan (5-HTP), 5-Hydroxyindoleacetic Acid (5-HIAA), 5-Hydroxytryptamine (5-HT), Adrenocorticotropic Hormone (ACTH), Biopsy, C-peptide, Calcitonin, Carcinoid crisis, Carcinoid heart disease, Carcinoid syndrome, Catecholamines, Chromaffin cells, Chromogranin, Chromogranin A (CgA), Chromogranin B (CgB), Chromogranin C (CgC), Cortisol, Electrolytes, Endocrine, Fasting Gut Endocrine Profile, Flushing, Gastric NET, Gastrin, Gastrin pH, Gastrinoma, Gastroesophageal reflux disease (GERD), Genetic testing, Glucagon, Glucagonoma, Hedinger syndrome, Histamine, Hormones, Hypertension, Insulin, Insulinoma, MEN1 syndrome, Metanephrines, Molecular markers, NETest, Neuroendocrine, Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Neurokinin A (NKA), NKA, NT-proBNP, Pancreastatin, Pancreatic cancer, Pancreatic NET (PanNET), Pancreatic polypeptide (PP), Pheochromocytoma, Plasma 5HIAA, PPoma, Proinsulin, Proton pump inhibitors (PPI), Red blood count (RBC), Renal insufficiency, Serotonin, Serum serotonin, Somatostatin, Somatostatinoma, Substance K, Substance P, Tachycardia, Tachykinin, VIPoma, Wheezing, Zollinger-Ellison Syndrome

Neuroendocrine Cancer – tumour markers and hormone levels

By Ronny Allan Dec 01, 2024 23 Comments

Originally published 2016, updated October 2025BackgroundSome people hear the terms "tumour markers" and "hormone levels" when they are diagnosed with Neuroendocrine Neoplasms (NENs). That might be confusing or even alarming at the time. Most people diagnosed with cancer will have had a form of medical testing at some point in their life, i.e. the sampling and testing of blood, urine, saliva, stool or body tissue. With NENs, the medical staff are just measuring the content of a 'substance' and then taking a view whether this is normal or not based on pre-determined ranges. These tests are normally done as a…

A spotlight on NENs - Types, Awareness, Patient Advocacy, Spotlight on NENs - Types Series123I-Metaiodobenzylguanidine (mIBG), 131I-Metaiodobenzylguanidine (mIBG), 18F-FDG, 18F-FDOPA, 24-hour urinary catacholamines and metanephrines, Adrenal glands, Adrenal medulla, Adrenaline, Adrenocortical Carcinoma (ACC), Anxiety, AZEDRA, Catecholamines, EPAS1, Epinephrine, Familial NET, FH, Ga68 PET/CT, Genetics, Hormonal crisis, Hormones, Hyperadrenergic, Hypertension, Intraoperative hypertensive crisis, Iobenguane I 131, MDH2, MEN2 syndrome, MIBG scan, Multiple Endocrine Neoplasia (MEN), Nausea, Neuroendocrine, Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), NF1, Octreotide scan, Palpitation, Pheochromocytoma, RET, Scan, SDHA, SDHAF2(SDH5), SDHB, SDHC, SDHD, Somatostatin analogues, Surgery, Sweating, Tachycardia, The 5 E's, Vanillylmandelic acid (VMA), Von Hippel-Lindau (VHL) Syndrome

Neuroendocrine Tumours: a spotlight on Pheochromocytoma and Paraganglioma

By Ronny Allan Dec 14, 2016 4 Comments

Updated 19th August 2025I spend a lot of time talking about the most common forms of Neuroendocrine Tumours (NETs), but what about the less well-known types? As part of my commitment to all types of NETs, I'd like to shine a light on two less common tumour types known as Pheochromocytomas and Paragangliomas - with an incidence rate of approximately 8 per million per year. They are normally grouped together, and the definitions below will confirm why. If you think it's difficult to diagnose a mainstream NET, this particular sub-type is a real challenge.So, let's get definitions out of the…